| 应用 |
A rationally designed c-Abl and Bcr-Abl kinase inhibitor |
| 产品介绍 |
Nilotinib (尼洛替尼; AMN-107) 是Bcr-Abl抑制剂，IC50小于30 nM。 |
| 备注 |
Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM. |
| 生化机理 |
Nilotinib is a small molecule Bcr-Abl kinase inhibitor, rationally designed to bind and inhibit the c-Abl kinase active site with more affinity than the prototypic Bcr-Abl kinase inhibitor Imatinib (sc-202180). Nilotinib demonstrates a high affinity for the kinase (IC50 < 30nM) and shows efficacy against chronic myelogenous leukemias (CML) expressing the Bcr-Abl oncogene/fusion protein, both the wild type and CMLs presenting Imatinib resistance. |
| 别名 |
尼罗替尼; 尼洛替尼;4-甲基-3-((4-(3-吡啶基)-2-嘧啶基)氨基)-N-(5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基)苯甲酰胺;;AMN-107; Tasigna; AMN107;4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide |
